Iovance Biotherapeutics (IOVA) Projected to Announce Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Iovance Biotherapeutics to announce earnings of ($0.17) per share and revenue of $87.6740 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, meeting analysts’ consensus estimates of ($0.19). Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The business had revenue of $71.43 million during the quarter, compared to analysts’ expectations of $77.84 million. During the same period in the prior year, the company earned ($0.36) earnings per share. The firm’s revenue was up 44.9% on a year-over-year basis. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Iovance Biotherapeutics Trading Down 3.0%

Shares of IOVA stock opened at $4.56 on Thursday. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $5.64. The stock has a market cap of $2.04 billion, a P/E ratio of -4.80 and a beta of 0.70. The company has a 50 day simple moving average of $4.29 and a two-hundred day simple moving average of $3.68.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IOVA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Chardan Capital decreased their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $8.43.

Institutional Investors Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Granite Investment Partners LLC bought a new position in shares of Iovance Biotherapeutics in the fourth quarter worth approximately $29,000. Motley Fool Asset Management LLC bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at $29,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Iovance Biotherapeutics during the 4th quarter valued at $46,000. HighTower Advisors LLC lifted its stake in shares of Iovance Biotherapeutics by 67.9% during the 4th quarter. HighTower Advisors LLC now owns 19,089 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 7,718 shares in the last quarter. Finally, Diversify Wealth Management LLC purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter valued at $34,000. Institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.